1
Return

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

delete2025-11-24
delete0
PRE
AI
F
Fabio Conforti
J
Johannes Holtschmidt
V
Valentina Nekljudova
I
Isabella Sala
E
Eleonora Pagan
C
Christine Solbach
M
Michael Untch
C
Carsten Denkert
V
Vincenzo Bagnardi
L
Laura Pala
P
Peter A. Fasching
A
Andreas Schneeweiß
H
Hans‐Joachim Lück
G
Giuseppe Viale
T
Tommaso De Pas
M
Marion van Mackelenbergh
J
Jens Huober
V
Volkmar Mueller
T
Theresa Link
T
Thomas Karn
DOI：10.1016/S1470-2045(25)00546-7delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The surrogacy value of distant disease-free survival for overall survival has not been validated in neoadjuvant randomised controlled trials (RCTs) for early breast cancer. Here, we assess the trial-level surrogacy value of distant disease-free survival for overall survival.

Journal

T
The Lancet Oncology
IF:
0
Papers:
348
Citations:
1

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers